```html

Zollinger‑Ellison Syndrome (MEN1)

Overview

Zollinger‑Ellison syndrome (ZES) is a rare condition characterized by one or more gastrin‑producing neuroendocrine tumors (gastrinomas) that usually arise in the pancreas or duodenum. The excess gastrin stimulates the stomach to secrete large amounts of acid, leading to severe peptic ulcer disease and a host of related gastrointestinal problems.

When ZES occurs as part of multiple endocrine neoplasia type 1 (MEN 1), patients also have a genetic predisposition to develop tumors in the parathyroid glands, pituitary gland, and other endocrine organs. MEN 1 is inherited in an autosomal dominant pattern, meaning a child of an affected parent has a 50 % chance of inheriting the mutation.

Who it affects

• MEN 1‑related ZES accounts for ~20‑25 % of all Zollinger‑Ellison cases.
• Both males and females are affected equally.
• Symptoms typically appear in the third to fifth decade of life, but MEN 1 carriers can develop gastrinomas as early as adolescence.

Prevalence

• MEN 1 overall prevalence: ~1–3 per 100,000 people worldwide (NIH).
• Zollinger‑Ellison syndrome (all causes): 0.1–1 per 100,000, with MEN 1 responsible for roughly 0.02–0.25 per 100,000.

Symptoms

Because excess gastric acid affects many parts of the digestive tract, ZES presents with a wide spectrum of signs. In MEN 1 patients, symptoms may overlap with other endocrine abnormalities (e.g., hypercalcemia from parathyroid disease).

Gastrointestinal Symptoms

• Recurrent peptic ulcers – often multiple, large, and located beyond the duodenum (e.g., jejunum, ileum).
• Epigastric or upper‑abdomen pain – burning or gnawing pain that may improve with food or antacids.
• Diarrhea – watery, sometimes nocturnal, due to acid‑induced malabsorption.
• Steatorrhea (fatty stools) – fat malabsorption from acid damage to the pancreas.
• Nausea & vomiting – especially after meals.
• Gastroesophageal reflux disease (GERD) – heartburn and regurgitation.
• Weight loss – from malabsorption and chronic diarrhea.

Systemic & MEN 1‑Related Symptoms

• Hypercalcemia – due to primary hyperparathyroidism (common in MEN 1); presents with fatigue, kidney stones, bone pain.
• Headaches, visual changes, or galactorrhea – may signal a pituitary adenoma.
• Fatigue, muscle weakness – can be multifactorial (acid loss, hypercalcemia, anemia).
• Skin changes – rare cutaneous neuroendocrine tumors (carcinoid) may appear.

Causes and Risk Factors

Zollinger‑Ellison syndrome is a tumor‑driven disease. In the context of MEN 1, the underlying cause is a germline mutation in the MEN1 gene, which encodes the tumor suppressor protein menin.

Genetic Cause

• MEN1 gene mutation – loss‑of‑function mutations remove menin’s ability to regulate cell growth, leading to multiple endocrine tumors, including gastrinomas.
• Over 1,300 distinct MEN1 mutations have been identified; most are inherited, but up to 10 % arise de novo.

Other Risk Factors

• Family history – a first‑degree relative with MEN 1 dramatically raises risk.
• Age – while gastrinomas can develop at any age, the median age of diagnosis in MEN 1 patients is ~35 years.
• Smoking & heavy alcohol use – may worsen ulcer disease but are not primary causes of gastrinomas.

Diagnosis

A combination of clinical suspicion, biochemical testing, imaging, and sometimes genetic testing is required.

Biochemical Tests

• Fasting serum gastrin level – markedly elevated (>1000 pg/mL) strongly suggests ZES; values >10× upper limit of normal are diagnostic when accompanied by gastric acid hypersecretion.
• Secretin stimulation test – in ZES, gastrin paradoxically rises >120 pg/mL after IV secretin (a hormone that normally suppresses gastrin).
• Basal acid output (BAO) or gastric pH – pH <2 indicates hyperacidity.
• Calcium, PTH, and vitamin D levels – to evaluate for MEN 1‑related hyperparathyroidism.

Imaging Studies

• Endoscopic ultrasound (EUS) – highly sensitive for small pancreatic/duodenal gastrinomas.
• Multiphasic contrast CT or MRI – locates larger tumors and assesses for metastasis.
• Somatostatin receptor scintigraphy (Octreoscan) or Ga‑68 DOTATATE PET/CT – detects neuroendocrine tumors expressing somatostatin receptors, helpful for staging.
• Selective arterial secretagogue injection (SASI) test – rarely used; localizes gastrinoma by measuring gastrin gradients after selective arterial infusion.

Genetic Testing

If MEN 1 is suspected (family history, multiple endocrine tumors), sequencing of the MEN1 gene is recommended. Identifying a pathogenic variant confirms the diagnosis and guides family screening.

Diagnostic Criteria (per NIH & WHO)

1. Fasting gastrin >1000 pg/mL OR positive secretin stimulation test.
2. Evidence of gastric acid hypersecretion (pH < 2 or BAO > 15 mEq/h).
3. Imaging confirmation of a gastrinoma (or metastasis) or genetic confirmation of MEN 1.

Treatment Options

Management is multidisciplinary, targeting acid hypersecretion, tumor control, and MEN 1‑related endocrine abnormalities.

Acid‑Suppressive Therapy (first line)

• Proton pump inhibitors (PPIs) – omeprazole, esomeprazole, pantoprazole. Doses are usually 2–4× the standard ulcer dose (e.g., omeprazole 60–80 mg daily). PPIs are the most effective way to control gastric acid and heal ulcers.
• H2‑receptor antagonists (e.g., ranitidine, famotidine) – less potent; may be added if PPIs are insufficient.

Surgical Management

• Local resection of gastrinoma – preferred when the tumor is isolated and <5 cm in size. Duodenal gastrinomas are often amenable to enucleation.
• Pancreaticoduodenectomy (Whipple procedure) – considered for large or invasive pancreatic gastrinomas.
• Debulking surgery – may reduce tumor burden in metastatic disease, improving symptom control.
• In MEN 1 patients, surgery is controversial because multiple micro‑gastrinomas are common; a tailored approach based on tumor size, growth rate, and patient age is recommended.

Medical Therapies for Tumor Control

• Somatostatin analogues (octreotide, lanreotide) – bind somatostatin receptors, inhibiting gastrin release and tumor growth. Useful for unresectable or metastatic disease.
• Targeted therapies – everolimus (mTOR inhibitor) and sunitinib (tyrosine‑kinase inhibitor) have FDA approval for progressive pancreatic neuroendocrine tumors; they can slow gastrinoma growth.
• Chemotherapy – rarely needed; regimens such as streptozocin + 5‑FU or temozolomide are reserved for aggressive disease.

Management of MEN 1‑Associated Conditions

• Hyperparathyroidism – surgical removal of overactive parathyroid tissue (parathyroidectomy) is often required.
• Pituitary adenomas – may need transsphenoidal surgery, dopamine agonists, or radiotherapy depending on size and hormone secretion.

Lifestyle & Supportive Measures

• Small, frequent meals; avoid foods that trigger acid (spicy, caffeinated, alcoholic).
• Stay hydrated; oral rehydration solutions help replace losses from diarrhea.
• Calcium and vitamin D supplementation if hyperparathyroidism is treated.
• Regular endocrinology follow‑up and annual imaging to monitor for new tumors.

Living with Zollinger‑Ellison Syndrome (MEN1)

Long‑term management focuses on symptom control, monitoring for tumor progression, and addressing the broader MEN 1 spectrum.

Daily Management Tips

1. Medication adherence – take PPIs exactly as prescribed; missing doses can precipitate ulcer bleeding.
2. Meal planning – low‑fat, low‑acid diet; chew food thoroughly; avoid lying down for 30 minutes after eating.
3. Hydration – aim for ≥2 L of water daily; use electrolyte solutions if diarrhea is frequent.
4. Bone health – after treating hyperparathyroidism, DEXA scans every 2–3 years; ensure adequate calcium (1,200 mg) and vitamin D (800–1,000 IU).
5. Regular labs – fasting gastrin, calcium, PTH, and vitamin D levels every 6–12 months.
6. Screening for other MEN 1 tumors – MRI of the pituitary every 3–5 years; neck ultrasound for parathyroids; consider repeat abdominal imaging annually.
7. Psychosocial support – connect with patient advocacy groups (e.g., MEN Network) and consider counseling to cope with chronic disease burden.

Family Planning

Because MEN 1 is autosomal dominant, each child of an affected individual has a 50 % chance of inheriting the mutation. Genetic counseling before conception and offering prenatal or pre‑implantation genetic testing are advisable.

Prevention

While the genetic mutation cannot be prevented, certain steps reduce disease burden and complications:

• Early genetic testing of at‑risk relatives allows surveillance before symptoms develop.
• Prompt treatment of hyperparathyroidism reduces calcium‑related kidney stones and bone loss.
• Smoking cessation and limiting alcohol lower the risk of ulcer complications.
• Adherence to PPI therapy prevents severe ulcer disease and bleeding.

Complications

If left untreated or poorly controlled, ZES (especially in MEN 1) can lead to serious health problems:

• Bleeding peptic ulcers – may require endoscopic hemostasis or surgery.
• Perforated ulcer – a surgical emergency with high morbidity.
• Gastrointestinal strictures – from chronic ulcer scarring, causing obstruction.
• Severe malabsorption – leading to nutritional deficiencies, weight loss, anemia.
• Metastatic gastrinoma – spreads to liver or lymph nodes; reduces survival.
• Kidney stones & osteoporosis – secondary to MEN 1‑related hyperparathyroidism.
• Pituitary apoplexy or visual loss – from enlarging pituitary adenomas.
• Psychological distress – chronic disease can cause anxiety and depression.

When to Seek Emergency Care

References

1. Mayo Clinic. “Zollinger-Ellison syndrome.” https://www.mayoclinic.org.
2. National Institutes of Health (NIH). “Multiple endocrine neoplasia type 1.” https://ghr.nlm.nih.gov.
3. American Cancer Society. “Pancreatic neuroendocrine tumors.” 2023.
4. Cleveland Clinic. “Management of Zollinger‑Ellison syndrome.” https://my.clevelandclinic.org.
5. European Neuroendocrine Tumor Society (ENETS) Guidelines, 2022.
6. World Health Organization (WHO). “Classification of endocrine tumors.” 2021.
7. UpToDate. “Approach to the patient with Zollinger‑Ellison syndrome.” (accessed April 2026).

```